Form 4 for SNDX Syndax Pharmaceuticals Inc

Accepted 2025-02-07 00:00:00 ET · period of report 2025-02-05 · accession 0000950170-25-016391 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
DM	2025-02-07	2025-02-05	SNDX	Gallagher Neil	Pres, Head of R, D	A - Grant	$0.00	+41.9K	66.3K	+172%	$0
D	2025-02-07	2025-02-05	SNDX	Gallagher Neil	Pres, Head of R, D	A - Grant	$14.65	+110.5K	110.5K	New	+$1.62M

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2025-02-05	A	A	23,400	$0.00	89,713	D	—	—	(F2) Award of RSUs, representing the right to receive one share of Common Stock for each RSU. The number of shares of Common Stock acquired upon vesting of the RSUs is contingent upon the achievement of pre-established performance metrics, as approved by the Company's Compensation Committee, subject to the Reporting Person's continued service as an employee, consultant, director or officer of the Company.
2	Common	Common Stock	2025-02-05	A	A	18,500	$0.00	66,313	D	—	—	(F1) Award of restricted stock units ("RSUs"), representing the right to receive one share of Common Stock for each RSU. One third (1/3rd) of the shares of Common Stock subject to such RSU shall vest annually on the anniversary of the Vesting Commencement Date, during the Reporting Person's continued service as an employee, consultant, director or officer of the Company over the three (3) years following the date of grant, until all of the shares subject to such RSU are fully vested.
3	Derivative	Stock Options (Right to buy)	2025-02-05	A	A	110,500	$14.65	110,500	D	$14.65 · — to 2035-02-05	110,500 Common Stock	(F3) 1/48th of the shares subject to the option shall vest monthly over a four-year period.